nonacog beta pegol

DRUG9 trials

Sponsors

Novo Nordisk A/S

Conditions

Congenital Bleeding DisorderHaemophilia B

Phase 1

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

CompletedNCT00956345

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia B

Start: 2009-08-31End: 2010-07-31Updated: 2017-01-20

Phase 3

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

CompletedNCT01333111

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia B

Start: 2011-04-27End: 2013-03-31Updated: 2017-07-28

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

CompletedNCT01386528

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia B

Start: 2012-06-07End: 2013-12-01Updated: 2017-08-23

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

CompletedNCT01395810

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia B

Start: 2012-04-15End: 2014-03-30Updated: 2018-05-09

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

CompletedNCT01467427

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia B

Start: 2012-05-16End: 2023-11-17Updated: 2025-12-23

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

CompletedNCT02141074

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia B

Start: 2014-07-02End: 2022-10-27Updated: 2025-12-23

A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B

CompletedNCT05365217

Novo Nordisk A/SHaemophilia B

Start: 2022-05-18End: 2024-05-11Updated: 2026-01-12

Unknown Phase

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

Enrolling by invitationNCT03690336

Novo Nordisk A/SHaemophilia B

Start: 2018-10-01End: 2027-10-01Target: 10Updated: 2025-06-02

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Enrolling by invitationNCT03745924

Novo Nordisk A/SHaemophilia B

Start: 2019-04-01End: 2027-12-15Target: 60Updated: 2026-06-12

Related Papers

Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP).

2019-12-017 citations

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

Blood2014-09-27180 citations

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

2011-05-09137 citations